Keeping You Updated
Here is a selection of recent PharmaVentures press releases...
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
Oxford, UK (PRWEB) June 24, 2009 -- PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday.
Roche:Genentech Integration Latest: Exclusive Interview on PharmaTelevision
Oxford, UK (PRWEB) June 4, 2009 -- PharmaTelevision announced today that it is to broadcast an exclusive interview with Dan Zabrowski, Global Head, Pharma Partnering, Roche Pharmaceuticals Division and Joe McCracken, Vice President, Business Development, Genentech, on the Roche:Genentech integration, on June 4th 2009.
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct® After Phase IIa Trial Achieves Clinical Endpoints Early
Oxford, UK- 18th May 2009 - PharmaVentures Ltd, announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD).
Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
Oxford, UK- 24 April 2009 - PharmaVentures Ltd, announced today that it has been engaged by Merck & Co, Inc. to advise and assist in divesting its world class research centre, the IRBM, located near Rome, Italy. The engagement will utilise PharmaVentures' pharmaceutical transactions experience in the healthcare and investment business sectors. The IRBM is an integrated, state-of-the-art small molecule and biological discovery centre. IRBM has an outstanding record of drug discovery including Isentress(R), the first approved HIV integrase inhibitor and winner of the Prix Galien USA 2008 award for the best pharmaceutical agent. The centre has received significant investment since 2000 and is staffed with exceptional, experienced pharmaceutical scientists.